Antibody therapy

Monoclonal antibodies target antigens expressed by malignant cells, making them more selective than chemotherapy. Antibodies can induce the innate immune response to destroy tumor cells, or block key extracellular sites such as receptors to induce cancer cell death. In MM, target antigens include BCMA, CD20, CD38, CD40, PD-1, and VEGF.

Filter by content:

Types

• AL amyloidosis
• BRAF
• Chromosomal aberrations
• COVID-19
• Deletion 17p
• Deletion 1p
• Favorable-risk
• Gain 1q
• High-risk
• KRAS
• MGCS
• MGUS
• MYC
• Newly diagnosed multiple myeloma
• NRAS
• Plasma cell dyscrasias
• Plasma cell leukemia
• Relapsed/refractory multiple myeloma
• Risk
• Smoldering multiple myeloma
• TP53
• Translocation (11;14)
• Translocation (14;16)
• Translocation (14;20)
• Translocation (4;14)

Therapeutics

• ALLO-647
• ALLO-715
• Allo-HSCT
• AMG 420
• Anitocabtagene autoleucel
• Anselamimab
• Antibody therapy
• AO-176
• Arlocabtagene autoleucel
• Atezolizumab
• Auto-HSCT
• Avelumab
• bb21217
• BCMA CAR-T
• Belantamab mafodotin
• Bendamustine
• Birtamimab
• Blinatumomab
• Bortezomib
• CAEL-101
• CAR therapy
• Carfilzomib
• Cemsidomide
• Cevostamab
• Checkpoint inhibitors
• Chemotherapy
• Ciltacabtagene autoleucel
• Clodronate
• Conjugated antibodies
• CS1 (SLAMF7) CAR-T
• Cyclophosphamide
• Daratumumab
• Denosumab
• Dexamethasone
• Doxorubicin
• Durvalumab
• Elotuzumab
• Elranatamab
• EM801
• Equecabtagene Autoleucel
• Etentamig
• Etoposide
• Fludarabine
• HBI0101
• HDP-101
• Iberdomide
• Idecabtagene vicleucel
• Immune modulators
• Inobrodib
• Isatuximab
• ISB 1342
• ISB 1442
• ISB 2001
• Ixazomib
• Lenalidomide
• Linvoseltamab
• Melflufen
• Melphalan
• Mezigdomide
• MOR202
• Nivolumab
• Nuclear receptor agonists
• OriCAR-017
• Orvacabtagene autoleucel
• Pamidronate
• Panobinostat
• Pembrolizumab
• Plerixafor
• Pomalidomide
• Prednisone
• PROTACS
• Proteasome inhibitors
• PVX-410
• Ramantamig
• Ricolinostat
• Selinexor
• T-cell engagers
• TAK-079
• Talquetamab
• Targeted protein degraders
• Teclistamab
• Thalidomide
• Venetoclax
• Vincristine
• Vorinostat
• Zevorcabtagene autoleucel
• Zoledronic acid

Congresses

• 2021 Symposium
• 2024 Symposium
• AACR 2020
• American Society of Hematology
• ASCO 2017
• ASCO 2018
• ASCO 2019
• ASCO 2020
• ASCO 2021
• ASCO 2022
• ASCO 2024
• ASCO 2025
• ASCO 2026
• ASH 2017
• ASH 2018
• ASH 2019
• ASH 2020
• ASH 2021
• ASH 2022
• ASH 2023
• ASH 2024
• ASH 2025
• COMy 2018
• COMy 2019
• COMy 2020
• COMy 2021
• COMy 2022
• EBMT 2019
• EBMT 2020
• EBMT 2021
• EBMT 2022
• EBMT 2025
• EHA 2017
• EHA 2018
• EHA 2019
• EHA 2020
• EHA 2021
• EHA 2022
• EHA 2023
• EHA 2024
• EHA 2025
• EHA 2026
• EMN 2021
• EMN 2022
• ESH 2017
• ESH 2018
• ESH 2019
• ESH 2024
• European Hematology Association
• European Society for Blood and Marrow Transplantation
• IMS 2022
• IMS 2023
• IMS 2024
• IMS 2025
• IMW 2019
• IMW 2021
• SOHO 2019
• SOHO 2024
• SOHO 2025

Trials

• ALCYONE
• ALLG MM23
• ANDROMEDA
• APOLLO
• AQUILA
• ASCENT
• ASPIRE
• ATLAS
• AURIGA
• Bela
• DRd
• Bellini
• BENEFIT
• BOSTON
• CA057-003
• CALGB 100104
• CAMMA-1
• CAMMA-2
• CaMMouflage
• CANDOR
• CARTITUDE-1
• CARTITUDE-2
• CARTITUDE-4
• CARTITUDE-5
• CARTITUDE-6
• CASSIOPEIA
• CASSIOPET
• CASTOR
• CC-220-MM-001
• CC-92480-MM-001
• CC-92480-MM-002
• CENTAURUS
• CEPHEUS
• COBRA
• COLUMBA
• CRB-401
• DETERMINATION
• DREAMM-1
• DREAMM-2
• DREAMM-3
• DREAMM-7
• DREAMM-8
• DREAMM-9
• E3A06
• ELOQUENT-1
• ELOQUENT-2
• ELOQUENT-3
• EMN18
• EMN19
• EMN20
• EMN26
• ENDEAVOR
• ENDURANCE
• EQUULEUS
• ERASMM
• EXCALIBER-Maintenance
• EXCALIBER-RRMM
• FiTNEsS
• FORTE
• FREEDOM
• FUMANBA-1
• GEM-BELA-VRd
• GEM-CESAR
• GEM-IBER
• DARAX
• GEM2012
• MENOS65
• GEM2014
• MAIN
• GEM2017
• FIT
• GEN501
• GMMG-CONCEPT
• GMMG-HD7
• GMMG-HG7
• GRIFFIN
• HORIZON
• Hovon 143
• I2D
• IFM2021_03
• ICARIA-MM
• ICONIDEAL
• IFM 2017-03
• IFM2005-02
• IFM2009
• IKEMA
• IMAGE
• IMMagine-1
• IMROZ
• IRIA
• ISABEL
• ISASOCUTISK
• KIAistop
• MMIZALCO
• JCOG1911/B-DASH
• KarMMa
• KarMMa-2
• KarMMa-3
• KarMMa-9
• LEGEND-2
• LINKER-AL2
• LINKER-MM1
• LINKER-MM2
• LocoMMotion

Expert Opinions

• Ajai Chari
• Alessandro Gozzetti
• Alexander Lesokhin
• Amrita Krishnan
• Anne Arber
• Ben Derman
• Brea Lipe
• Bruno Paiva
• Chengcheng Fu
• Christine Spencer
• Clifton Mo
• Cristina Gasparetto
• Diwakar Davar
• Efstathios Kastritis
• Elena Zamagni
• Elizabeth O'Donnell
• Enrique Ocio
• Francesca Gay
• Gordon Cook
• Graham Jackson
• Hang Quach
• Heinz Ludwig
• Hermann Einsele
• Irene Ghobrial
• Jacob P. Laubach
• Jeffrey Wolf
• Jesus G. Berdeja
• Jonathan L. Kaufman
• Katja Weisel
• Krina Patel
• Leo Rasche
• Luciano Costa
• Marc S. Raab
• Marc-Andrea Bärtsch
• María-Victoria Mateos
• Martin F. Kaiser
• Matthew Drake
• Meletios Dimopoulos
• Meral Beksaç
• Michel Delforge
• Miles Prince
• Mohamad Mohty
• Morie Gertz
• Nico Gagelmann
• Niels van de Donk
• Nikhil Munshi
• Nina Shah
• Nizar Bahlis
• Noopur Raje
• Omar Nadeem
• Paul Richardson
• Paula Rodriguez Otero
• Peter Voorhees
• Philippe Moreau
• Rakesh Popat
• Ravi Vij
• Roman Hájek
• Rui Bergantim
• Saad Usmani
• Sagar Lonial
• Shaji Kumar
• Smith Giri
• Sonja Zweegman
• Suzanne Lentzsch
• Thomas Martin
• Timothy M. Schmidt
• Vania Tietsche de Moraes Hungria
• Vincent Rajkumar

Educational Resources

• Diagnostic and treatment guidelines
• Drug approvals
• Focused reviews
• Masterclass
• Multiple Myeloma Hub symposiums
• Special populations
• Spotlights
• Steering Committee meetings
• Supportive care
• Visual abstracts

Content Statistics

• 427 articles
• 31 podcasts
• 17 resources
• 9 congress feeds
• 106 videos